Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options
Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options |
| [27-June-2018] |
OSLO, Norway, June 27, 2018 /PRNewswire/ -- A participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO) previous employee share option program, not being a primary insider, has exercised a total number of 41,246 options through exercise of a corresponding number of free-standing warrants. 10,413 of the shares are exercised at a strike price of NOK 14.24 per share, and 30,833 of the shares are exercised at a strike price of NOK 34 per share. Each free-standing warrant gives the right to receive one share in the Company. Following exercise of the 41,246 free-standing warrants, the Company's registered share capital was increased by NOK 8,249.2 through issuance of 41,246 new shares, each with a nominal value of NOK 0.20, against payment of a total subscription price of NOK 1,196,603. Following the share capital increase the Company has a share capital of NOK 9,817,129.6 divided on 49,085,648 shares, each with a par value of NOK 0.20. About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. CONTACT: For further information, please contact: Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44-7561-431-762 Email: ir@nordicnanovector.com This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector | ||
Company Codes: Bloomberg:NANO@NO, ISIN:NO0010597883, Oslo:NANO, RICS:NANO.OL |
View original content:© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}
